



Entrepreneurial &
Skilled Education
for the Future



Volume 5, Issue 2 - MAY 2026

IQ RESEARCH

A Quaterly Journal

ISSN: 2790-4296 (Online)

ISBN: 978-9956-504-74-9 (Print)

Published by IQRJ publications
www.iqresearchjournal.com



EDITORIAL BOARD

Editor-in-Chief

- ◆ Atanga D. Funwie (Professor) — Kesmonds International University / Nile University of Science & Technology / Green Hope University Somalia

Deputy Editor-in-Chief

- ◆ Dr. Mvogo Eloundou Guy Dieudonné, PhD, Public Health, Tropical Medicine and Infectious Diseases / Kesmonds International University

Associate Editor-in-Chief

- ◆ Tchouaffe Tchiadje Norbert (Professor) — Kesmonds International University / Massachusetts Institute of Technology USA / Pan African University

Editorial Assistants

- ◆ Professor Tchakounte Franklin — Kesmonds International University / University of Ngaoundere
- ◆ Professor Akah Roland Tiagha — Kesmonds International University / Walter Sisulu University South Africa
- ◆ Professor Guiherme Schneider — Mexico
- ◆ Professor Charles Fokunang — Cameroon Ethics Society / University of Yaounde 1
- ◆ Professor Tassang Ndah Andrew — Kesmonds International University / University of Buea
- ◆ Professor Daniel Tata — Switzerland
- ◆ Professor Truly Bush — Germany
- ◆ Professor Abraham Pius — The Academy of Advance Science, United Kingdom
- ◆ Professor Celestina Neh Tassang — University of Buea
- ◆ Professor Letlole Gabriel Gonnafela — Gonnafela Institute South Africa / Kesmonds International University
- ◆ Professor Patricia Samkia Asongwe — Ministry of Higher Education Cameroon
- ◆ Professor Sama Dobit — University of Yaounde I
- ◆ Professor Tony Ogiemen — American Heritage University of Southern California, USA
- ◆ Professor Gabriel Lopes — Unilogos University, USA and Brazil
- ◆ Professor Nukenine Elias — University of Ngaoundere
- ◆ Professor Neossi Guena Mathurin — University of Ngaoundere / Ngaoundere Regional Hospital
- ◆ Professor Angwanade Wilson — University of Ngaoundere
- ◆ Professor Esther Ngah — University of Ngaoundere
- ◆ Professor Yongho Shiwoh Louis — Kesmonds International University
- ◆ Professor Asakizi Nji Augustine — Kesmonds International University / University of Bamenda Cameroon
- ◆ Professor Rudolph Q. Kwanue — Rudolph Kwanue University Liberia
- ◆ Professor Mustaf Abdulle — President Green Hope University Somalia
- ◆ Professor Mathan Muse — Green Hope University Somalia / Nile University of Science & Technology
- ◆ Professor Lawrence Mwelwa — Queens College Zambia
- ◆ Professor Ibrahim Abdi — Green Hope University Somalia / Nile University of Science & Technology
- ◆ Professor Hussein Tohow — VC Green Hope University Somalia
- ◆ Professor Henry N. Fonjock — Cameroon Cooperative Credit Union
- ◆ Professor Zahir Shah — Professional Development Research Institute Pakistan
- ◆ Professor Brian Siamani — Dean Faculty of Medicine, Gideon Roberts University Zambia
- ◆ Professor Ernest Mutale — Ministry of Health Zambia
- ◆ Professor Kouam Lawrence — Kesmonds International University / University of Ngaoundere
- ◆ Professor Pascal Scheneller — Germany
- ◆ Professor Francis Pol Lim — Philippine
- ◆ Professor Mvondo M. Manuella — Kesmonds International University / University of Ngaoundere
- ◆ Professor Tamo Simo Richard — Kesmonds International University / University of Ngaoundere
- ◆ Professor Fodouop Simeon Pierre Tchegaing — Kesmonds International University / University of Ngaoundere
- ◆ Professor Elie Baudelaire — EMIE Business School Paris France
- ◆ Professor Sundjo Fabien — Kesmonds International University / University of Bamenda
- ◆ Professor Gidoen Mwanza — Gidoen Robert University Zambia

- ◆ Dr. Christina Jean Rahm — Institute of Clinical Research USA
- ◆ Dr. Oscar Monono — Ballbridge University
- ◆ Dr. Feugueng Micheal — Kesmonds International University United Kingdom
- ◆ Dr. Penya Elvis Che — Kesmonds International University / St John Paull II University Cameroon
- ◆ Dr. Shei Claude Nfor — Shalom Institute Cameroon
- ◆ Dr. Kabonbe Achile — Kesmonds International University / University of Ngaoundere
- ◆ Dr. Doudou Raisa — Ministry of Scientific Research Cameroon
- ◆ Dr. Zilefac Ebenezer Nwetlagwung — Kesmonds International University / Southeast University China

Editorial Secretaries

- ◆ Gana Christophe — Kesmonds International University
- ◆ Kalwa Yvette — Kesmonds International University
- ◆ Eng. Benson Lugalia — Kesmonds Group Limited
- ◆ Eng. Pokam Tchinda Martial — Kesmonds International University / University of Ngaoundere
- ◆ Dr. Kelly Kesten Manyi Atanga — Kesmonds International University / Jining Medical University, China
- ◆ Dr. Pauline Wanjiru Gititha — Kesmonds International University
- ◆ Dr. Eng. Anyangwe C. Anyangom — Kesmonds Group Limited, Kesmonds Institute of Technology

Editorial Board Members

- ◆ Prof. Nicolas Guanzon Ong, Ph.D. — Department of Teaching Languages, University of Science and Technology of Southern Philippines
- ◆ Prof. Ibrahim Hussein — Kesmonds Research Institute Uganda
- ◆ Prof. Zapryan Assen — Higher School of Security and Economics, Plovdiv
- ◆ Prof. Surendra Kumar Gautam — Department of Chemistry, Tri-Chandra Campus, Tribhuvan University, Kathmandu, Nepal
- ◆ Prof. SENHADJI L. — Oran University Hospital, Department of Anesthesia-Intensive Care
- ◆ Prof. Sabyasachi Pramanik — Department of Computer Science and Engineering, Haldia Institute of Technology
- ◆ Prof. Meron Mersha — Quantum Optics and Information, Arba Minch University, Ethiopia
- ◆ Prof. Dr. Zahir Shah — Kesmonds Research Institute, Pakistan
- ◆ Prof. Dr. Bond Richard — California South University (CSU), Irvine, California, USA
- ◆ Prof. Dr. Abubakar Mohammad — University of Technology, Baghdad, Iraq
- ◆ Prof. Charlanne Miller — LIGS University Hawaii, Canada
- ◆ Prof. Ali Usman — (Ethiopia)
- ◆ Prof. Ali Abdul-Hussain Ghazzay — Department of Biology, University of AL-Qadisyah, Iraq
- ◆ Prof. Nana Anabel — (Ghana)
- ◆ Dr. Leonard Ake — Maitre-Assistant du CAMES, Enseignant-chercheur, Universite Boubacar Ba de Tillaberi
- ◆ Dr. Wilson Dabuo Wiredu — MOCS, VC Academics Affairs, DMTU, Ghana
- ◆ Dr. Wansso Blakwe Ahmed
- ◆ Dr. Vijay Ramkisan Lakwal — Department of Zoology, Science and Commerce College, Jalgaon (MS), India
- ◆ Dr. Veronica Blade — (Algeria)
- ◆ Dr. Velinga Ndolok Aime Cesaire — Ph.D. in Public Health Epidemiology, UNDP Public Health Development Program
- ◆ Dr. Uthman Simeon Adebisi — Obafemi Awolowo University, Nigeria
- ◆ Dr. Tumi Humphred Simoben — Ph.D. in Public Health, Kesmonds Research Institute
- ◆ Dr. Toffic Abdel Hassan — Plant Protection Research Institute, Agricultural Research Center
- ◆ Dr. Thomas Abraham — Department of Hotel Management, Gondar, Ethiopia
- ◆ Dr. Tchifam Berthe — Ph.D. in Public Health Epidemiology, Faculty of Medicine Garoua Cameroon
- ◆ Dr. Tatoh Adeline Manjuh — Ph.D. in Healthcare Administration, Limbe Referral Hospital Cameroon
- ◆ Dr. Tateukam Alphonse — Doctor of Clinical Medicine, Kesmonds Research Institute
- ◆ Dr. T. Christina Mondimu — University of Gondar, Ethiopia
- ◆ Dr. Surachita Basu — (Bangalore, India)
- ◆ Dr. Sujita Darmo, ST., MT — Mechanical Engineering, Mataram University, Indonesia
- ◆ Dr. Shehuri Sharon — Department of Botany, Faculty of Biosciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria
- ◆ Dr. Rofrigo Jose Pablo — Universidad Empresarial De Costa Rica
- ◆ Dr. Rintu Sayak — (India)
- ◆ Dr. Resham Kumari — Professor Assistant of Agricultural Zoology, Plant Protection Department, Sohag University, Egypt
- ◆ Dr. Renato Dan A. Pablo II — CSPE, Mabalacat City College

- ◆ Dr. Ranendu Dutta Pukayastha — S.J.N.P.G College, Lucknow, India
- ◆ Dr. Rajinder Singh Sodhi — Guru Kashi University, Ilorin, Nigeria
- ◆ Dr. Rajat Mrinal Kanti, PhD, D. LITT — Physiotherapist, NIMHANS, Bangalore, India
- ◆ Dr. Rafah Almutarreb — School of Computer Science and Technology, Algoma University, Canada
- ◆ Dr. Rabindra Das Sinha — (Chennai, India)
- ◆ Dr. R. Francis Kaundra — DMI-St. Eugene University, Great North Road, Chibombo District, Lusaka, Zambia
- ◆ Dr. Priyanka Weerasekara — Faculty of Social Sciences & Languages, Sabaragamuwa University of Sri Lanka
- ◆ Dr. Pawan Thapa — Department of Geomatics Engineering, School of Engineering, Kathmandu University, Nepal
- ◆ Dr. Osman Ibrionke — Abia State University Uturu, Nigeria
- ◆ Dr. Osama Mohamed Anwar Nofal — Emeritus Professor, National Research Centre
- ◆ Dr. Onwubere Isabella — Sub-Dean, Samuel Obiajulu University, Osun State, Nigeria
- ◆ Dr. Onodugu Obinna Donatus — Department of Mathematics, Faculty of Physical Sciences, Abia State University, Nigeria
- ◆ Dr. Ola Sayed Mohamed Ali — Girls-AL-Azhar University, Cairo
- ◆ Dr. Okpala Sunday Ocheni — University of Mosul, College of Science, Biology Dept.
- ◆ Dr. Obike Godwill Ukamaka, M.Sc, Ph.D. — (Medical Microbiology), Jos, Plateau State, Nigeria
- ◆ Dr. Obafemi Emmanuel — Adekunle Ajasin University Akungba Akoko, Ondo State
- ◆ Dr. Nzuzi Rafael — Bakhita African Schools, Butembo
- ◆ Dr. Nwatu Celestine Chibuzu — Rivers State University, Nigeria
- ◆ Dr. Nouma Simon Joachim — Ph.D. in Political Economics, Consultant and Auditor Bank of Central African States
- ◆ Dr. Ngwa Mathias — Faculty of Laws and Political Sciences, University of Dschang, Cameroon
- ◆ Dr. Nazar Hassan — PMAS Arid Agriculture University, Rawalpindi
- ◆ Dr. Nadia Jamil — Department of Environmental Sciences, Hazara University, Mansehra
- ◆ Dr. Mulani Moshin Anware — Sant Ramdas Art's, Commerce and Science College, Maharashtra
- ◆ Dr. Muhammad Farooq — Assistant Professor (Economics), Okara University, Pakistan
- ◆ Dr. Mohammad Usman Awan — Centre for Biotechnology and Microbiology, University of Swat
- ◆ Dr. Mohamed Mustaf Abdulle — Green Hope University Somalia / Nile University of Science & Technology
- ◆ Dr. Mochammad Munir Rachman, M.Si. — PGRI Adi Buana University Surabaya, Indonesia
- ◆ Dr. Mahmoud Magdy Abbas — Plant Nutrition Dept., Dokki, Giza, Egypt
- ◆ Dr. Lukong Hubert Shalanyuy — Kesmonds Research Institute
- ◆ Dr. Liela Meta — Malla Reddy Institute of Technology and Science
- ◆ Dr. Kheambo Didier — Ph.D. in Healthcare Administration, Kesmonds Research Institute
- ◆ Dr. Khan Aneeka Habib — College of Business Administration, International University of Business Agriculture and Technology, Dhaka, Bangladesh
- ◆ Dr. Kabul Amid Aabbasi — University of Karachi, Pakistan
- ◆ Dr. Jesica Gate — (France)
- ◆ Dr. Javnyuy Joybert, MBA, DBA — CEO CELBMD Africa, Douala Cameroon
- ◆ Dr. Jason Chishime Mwanza — St. Eugene University, Lusaka, Zambia
- ◆ Dr. Ilayaraja Degu Kathirkaman — Department of Geology, Gondar, Ethiopia
- ◆ Dr. Ibrahim Mohammad Almoselhy — Food Science and Technology, Faculty of Agriculture, Ain Shams University, Cairo, Egypt
- ◆ Dr. Hossain Johangir — Bangladesh
- ◆ Dr. Habiba Aissatou — (Egypt)
- ◆ Dr. Geoffrey Kingibe — Department of Sustainable Agriculture, Tamale Technical University, Tamale
- ◆ Dr. Frederick Mbogo Akoth, PhD — Department of Computer Science and Software Engineering, Bondo, Kenya
- ◆ Dr. Francis Onyango, Ph.D. — Nairobi, Kenya
- ◆ Dr. Fitsum Etefa — Ethiopian Institute of Textile and Fashion Technology [EiTEX], Ethiopia
- ◆ Dr. Farhat Samreen — Federal Urdu University of Arts, Karachi, Pakistan
- ◆ Dr. Fahid Faryal Yawar — Kabul Polytechnic University, Kabul, Afghanistan
- ◆ Dr. Fadekemi Williams Oyewusi — Imo State Polytechnic, Umuagwo, Nigeria
- ◆ Dr. Ezedimora Louise Ocheni — School of Special Education, Federal College of Education, Oyo, Oyo State
- ◆ Dr. Emmanuel Muhairwa — Dodoma University of Dodoma, Tanzania
- ◆ Dr. Emilia Kheambo, CPA(Z) — Senior Lecturer, Faculty of Commerce, GSBM
- ◆ Lecture, Bijay Nera Poudel — Tribhuvan University, Trichandra Multiple Campus, Department of Psychology, Kathmandu, Nepal
- ◆ Dr. Emili Burnley — (Canada)
- ◆ Dr. Doudou Nafissatou — Ministry of Scientific Research Cameroon

- ◆ Dr. Djibrilla Yaouba — World Bank Public Health Development Program Northern Cameroon / University of Ngaoundere Cameroon
- ◆ Dr. Desmond Olushola — Microbiology Department, Kogi State University, Anyigba
- ◆ Dr. Deric Chang Tektook — Iraq
- ◆ Dr. Debashi Panna — India
- ◆ Dr. David Dowland — Habibullah Bahar University College, Dhaka
- ◆ Dr. Danish Armed, Joel Caleb — Uturu
- ◆ Dr. Celestine Mulugeta Degu — College of Business and Economics, Wollega University
- ◆ Dr. Camile Rodriguezz — (Malaysia)
- ◆ Dr. Biokgololo Abeltine — Faculty of Commerce & Business Administration, Gaborone University College, Botswana
- ◆ Dr. Bella Perez — (Canada)
- ◆ Dr. Bashir Zainab — Social Studies Department, Tai Solarin College of Education, Omu-Ijebu, Ogun State, Nigeria
- ◆ Dr. Baratha Dewannara — Bolton University, (UK) (Sri Lankan Branch)
- ◆ Dr. Baba Batoure — Ph.D. in Health Economics, Director State Registered Nursing School Garoua Cameroon
- ◆ Dr. Aya Khalil Ibrahim Hassan Moussa — Biological Anthropology Department, Medical Research Division, Cairo, Egypt
- ◆ Dr. Asanath Dira — (Cairo, Egypt)
- ◆ Dr. Ambarish Sachin Bhalandhare — Associate Professor of Economics, India
- ◆ Dr. Ali Zehra Zaida — Guru Kashi University, Bathinda, Punjab
- ◆ Dr. Ali Mushin Haji — Dean of College of Science, Al-Karkh University of Science, Baghdad, Iraq
- ◆ Dr. Akinsola Gloria Adedaja M. Hamed — Department of Mathematics, Yobe State University, Damaturu, Nigeria
- ◆ Dr. Adeshini Goke Francis — Al-Hikmah University, Ilorin, Nigeria
- ◆ Dr. Adda Goudougou — Garoua General Hospital Cameroon
- ◆ Dr. Abrima Francis — Post-Doctoral Researcher, American International University West Africa, The Gambia
- ◆ Dr. Abraham Aziz — (Bangalore, India)
- ◆ Dr. Abhishek B. — Assistant Professor, SRM University, Kattankualthur, Chennai, India
- ◆ Chan Dong Hyun, Bs, Ms, Ph.D., Geology — The Chinese University of Hongkong
- ◆ Dr. Abdul Malik — Minhaj University, Lahore, Pakistan
- ◆ Dr. Abdul Hussain — Department of Botany, GPGC Parachinar, District Kurram
- ◆ Dr. (Mrs.) T V Sanjeevanie — General Sri John Kotelawala Defence University, Sri Lanka
- ◆ Dr. Mubeena Munir — Oromia State University and Jimma University
- ◆ Dr. Lingbe Soconde — Kesmonds International University / University of Garoua Cameroon
- ◆ Dr. Garam Garam — Kesmonds International University / University of Garoua Cameroon
- ◆ Dr. Edward Mutengechi — Makere University, Mulago Hospital Uganda
- ◆ Dr. Awah Richard Ndo — Cameroon Cooperative Society
- ◆ Dr. Abel Tadesse Belle K. — Jigjiga University, Jigjiga, Ethiopia
- ◆ Alobwede Pende Divine — Kesmonds International University
- ◆ Aissatou Missira — Kesmonds International University
- ◆ Paule Giovani Henriette — Kesmonds International University
- ◆ Nsuh Larissa — Kesmonds International University
- ◆ Nougho Nancy Merveille — Kesmonds International University
- ◆ Nfon Sergius Nfon — Kesmonds International University / University of Garoua Cameroon
- ◆ Ndapeyouene M. Zenabou — Kesmonds International University
- ◆ Mbanwie Nadege Ambeck
- ◆ Kalwa Yvette, Kesmonds International University
- ◆ Gana Christophe, Kesmonds International University



Entrepreneurial
Education for a
Changing Society



Table of Contents

Susceptibility Patterns of *Candida albicans* and Non-*albicans* Species in Immunocompromised Patients: Insights from a Hospital-Based Study in Cameroon..... **33**



Susceptibility Patterns of *Candida albicans* and Non-*albicans* Species in Immunocompromised Patients: Insights from a Hospital-Based Study in Cameroon

Che Amadine Lem^a, Augustine Nji Asakizi^a and Forcham Emmanuel Duna^a

Affiliations

- a. ^a School of Health and Biomedical Sciences, Kesmonds International University of America

ABSTRACT

Antifungal resistance in *Candida* species challenges infection management in immunocompromised patients in resource-limited settings. This cross-sectional study at Bamenda Regional Hospital, Cameroon (January–June 2025), evaluated susceptibility patterns of *Candida albicans* and non-*albicans* species (*C. glabrata*, *C. tropicalis*) from 500 immunocompromised participants (87.2% female, mean age 31.2 years) across oral, gastrointestinal (GI), and vulvovaginal (VVC) sites. Samples were analyzed per CLSI M44-A2 standards. Prevalence was 3.4% (oral), 5.8% (GI), and 26.6% (VVC) for *C. albicans*, and 1.2%, 2.0%, and 8.4% for non-*albicans* species. Clotrimazole showed 100% sensitivity for *C. albicans* oral isolates, itraconazole 95% for GI, flucytosine 98% for VVC; griseofulvin was resistant (0%). Fluconazole sensitivity was 80% (*C. albicans*), 60% (non-*albicans*). Statistical analyses confirmed associations (chi-square: $X^2= 32.4$, $p<0.001$; ANOVA: $F=4.56$, $p=0.012$; Kruskal-Wallis: $H=9.87$, $p=0.007$). Molecular mechanisms, including ERG11 mutations, efflux pumps, and biofilms, drive resistance in African isolates. Findings align with WHO antimicrobial resistance priorities, emphasizing enhanced surveillance and stewardship.

Keywords : *Candida albicans*, Non-*albicans Candida*, Antifungal Susceptibility, Immunocompromised Patients, Molecular Resistance, Cameroon

Corresponding Author:

Che Amadine Lem
Email: cheamadine@gmail.com

Paper ID: IQRJ-V05102-26005006

1. INTRODUCTION

Candida albicans and non-*albicans* species, including *C. glabrata* and *C. tropicalis*, are leading causes of opportunistic infections such as oral candidiasis, gastrointestinal (GI) candidiasis, and vulvovaginal candidiasis (VVC) in immunocompromised patients, particularly those with HIV (CD4 <200 cells/ μ L) (Lamont et al., 2006; Kasper et al., 2005). Cameroon having a prevalence of HIV of 3.7%, clearly outlining candidiasis as a significant public health burden (UNAIDS, 2019). Candidiasis non the less have been seen to cause significant burdens to these individuals with Identifiable risk factors such as mouth sores, white patches, nausea, constipation, vaginal discharge, and pains during sex (Ambe et al., 2020; Ngouana et al., 2025).

Antifungal resistance has been seen as a rising trend over the years driven by molecular mechanisms such as ERG11 mutations, efflux pumps (CDR1/CDR2, MDR1), and biofilm formation, which have severely limited treatment options in resource-limited settings (Berman and Krysan, 2020; Bhattacharya et al., 2020). None the less, most susceptibility testing have revealed high efficacy for antifungal medications such as clotrimazole (for most *C. albicans* oral isolates), itraconazole (for the majority of gastrointestinal candida infections), and flucytosine (for the majority of VVC infections). Also, studies have found a complete resistance to antifungal therapies such as griseofulvin and reduced fluconazole sensitivity (Pappas et al., 2016). Limited diagnostic infrastructure in Cameroon based on studies exacerbates resistance risks, with over-the-counter antifungal use being seen as the major contributing to resistance emergence (Ngouana et al., 2017). This study was aimed at determining site-specific prevalence, evaluating antifungal susceptibility, identifying risk factors, and elucidating molecular mechanisms driving resistance in *C. albicans* and non-*albicans* species.

2. RELATED WORKS

Antifungal resistance in *Candida* species is a well-documented global challenge. Berman and Krysan (2020) reviewed resistance mechanisms, including efflux pumps, ergosterol biosynthesis alterations, and biofilms, emphasizing the need for routine susceptibility testing to guide therapy. Pappas et al. (2016) provided updated Infectious Diseases Society of America (IDSA) guidelines, advocating site-specific antifungal therapies to optimize outcomes.

In Cameroon, Ambe et al. (2020) reported a 30–40% prevalence of oral candidiasis in HIV-positive patients, with risk factors including diabetes, poor oral hygiene, and low CD4 counts. Ngouana et al. (2025) documented high VVC prevalence, linked to hormonal contraceptives and immunosuppression. The World Health Organization lists *Candida* as a priority pathogen due to increasing resistance globally (World Health Organization, 2025a).

Comparative studies across Africa highlight regional variations in resistance patterns. Abrantes et al. (2014) found lower azole resistance in South African *C. albicans* isolates compared to non-*albicans* species, such as *C. glabrata*. Feglo and Narkwa (2015) and Kwamin et al. (2013) reported fluconazole resistance in Ghana ranging from 4.5% to 48.1% for *C. albicans* and higher for non-*albicans* species, driven by overuse of antifungals. ElFeky et al. (2016) noted that non-*albicans* species, particularly *C. glabrata* and *C. tropicalis*, accounted for 70% of VVC cases in Egypt, with elevated azole resistance. Africa and Abrantes (2016) reported azole resistance exceeding 50% in Cameroonian

C. albicans isolates, attributed to unregulated antifungal access and limited diagnostic capacity. Badiee et al. (2017) observed higher

resistance in infecting versus colonizing isolates in Iran, while Freitas et al. (2023) and Ahmad et al. (2022) noted similar trends in Brazil and India, respectively, underscoring the global spread of resistance.

2.1. Molecular Resistance Mechanisms in African Isolates

In African isolates, *C. albicans* resistance is primarily driven by **ERG11 mutations**, which alter lanosterol 14-demethylase, reducing azole binding affinity, and **efflux pumps** (CDR1/CDR2, MDR1), which actively expel azoles from fungal cells (Bhattacharya et al., 2020; Vanden Bossche et al., 1998). In Cameroon, ERG11 mutations contribute to azole resistance rates exceeding 50% (Africa and Abrantes, 2016). Non-*albicans* species exhibit distinct mechanisms: *C. glabrata* demonstrates intrinsic fluconazole resistance through CDR1 overexpression, while *C. tropicalis* upregulates both ERG11 and MDR1 genes (Kwamin et al., 2013; Abrantes et al., 2014). **Echinocandin resistance**, linked to FKS1/FKS2 mutations in the glucan synthase gene, is emerging in *C. glabrata*, reducing susceptibility to drugs like caspofungin (Perlin, 2017). **Biofilm formation**, particularly in VVC, creates drug-impermeable matrices, further enhancing resistance (Nett and Andes, 2010). **Aneuploidy** and epigenetic changes accelerate resistance evolution by altering gene copy numbers (Selmecki et al., 2006). Unregulated over-the-counter antifungal use in sub-Saharan Africa amplifies these mechanisms, as self-medication drives selective pressure (Africa and Abrantes, 2016).

2.2. Epidemiological Context in Africa

Sub-Saharan Africa accounts for 70% of global HIV cases, significantly driving candidiasis

prevalence (UNAIDS, 2019). In Cameroon, azole resistance in *C. albicans* exceeds 50

3. MATERIALS & METHODS

This cross-sectional study, conducted from January to June 2025 at Bamenda Regional Hospital, Cameroon, enrolled 500 immunocompromised participants, primarily those with HIV (CD4 <200 cells/ μ L) or diabetes. **Inclusion criteria** included confirmed immunocompromised status and informed consent; **exclusion criteria** comprised antifungal use within two weeks prior to enrollment. Structured questionnaires collected: - **Demographic data**: Age, sex, marital status, income, religion. - **Clinical symptoms**: Mouth sores, white patches, nausea, constipation, vaginal discharge, pain during sex. - **Antifungal history**: Prior use, duration, and type of antifungals.

Samples (oral swabs, stool, high vaginal swabs) were collected and cultured for *C. albicans* and non-*albicans* species (*C. glabrata*, *C. tropicalis*) on Sabouraud dextrose agar. Species identification was confirmed via germ tube tests and CHROMagar. Susceptibility testing followed CLSI M44-A2 guidelines (Clinical and Laboratory Standards Institute, 2010), assessing minimum inhibitory concentrations (MICs) for clotrimazole, itraconazole, flucytosine, fluconazole, and griseofulvin using disk diffusion methods.

Statistical analyses were performed using SPSS v21.0. Descriptive statistics (frequencies, means \pm standard deviation) summarized demographics, prevalence, and susceptibility patterns. Chi-square tests evaluated associations between infection sites and susceptibility:

$$\chi^2 = \sum \left(\frac{(O_i - E_i)^2}{E_i} \right)$$

where O_i is observed frequency and E_i is expected frequency. ANOVA compared mean susceptibility across antifungals:

$$F = \frac{\text{Between group variability}}{\text{Within group variability}}$$

Kruskal-Wallis tests validated non-parametric differences:

$$H = \left[\frac{12}{N(N+1)} \sum_{i=1}^k \frac{R_i^2}{n_i} \right] - 3(N+1)$$

where R_i is rank sum and K is group size. Post-hoc Tukey tests identified specific group differences. Statistical significance was set at $p < 0.05$. Ethical approval was obtained from the Regional Delegation of Public Health, Cameroon.

4. RESULTS & DISCUSSION

4.1. Demographics and Prevalence

The study population ($n=500$) was 87.2% female ($n=436$), with a mean age of 31.2 ± 7.2 years. Most participants were aged 28–37 (51.2%, $n=256$), married (59.4%, $n=297$), Christian (99%, $n=495$), and earned <50,000 XAF monthly

(55.6%, $n=278$). Prevalence for *C. albicans* was 3.4% (oral, $n=17$, 95% CI: 1.8–5.0), 5.8% (GI, $n=29$, 95% CI: 3.8–7.8), and 26.6% (VVC, $n=133$, 95% CI: 22.7–30.5). Non-albicans species prevalence was 1.2% (oral, $n=6$), 2.0% (GI, $n=10$), and 8.4% (VVC, $n=42$), totaling 11.6% ($n=58$, 95% CI: 8.8–14.4).

4.2. Susceptibility Patterns

For *C. albicans*, susceptibility was highest for clotrimazole (100% for oral isolates), itraconazole (95% for GI), and flucytosine (98% for VVC), with fluconazole at 80% and griseofulvin at 0% across all sites. Non-albicans species showed lower susceptibility: clotrimazole 65%, itraconazole 70%, flucytosine

60%, fluconazole 60%, and griseofulvin 0% (Table 2). Statistical analyses confirmed significant associations between infection site and susceptibility (chi-square: $X^2 = 32.4$, $p < 0.001$), differences across antifungals (ANOVA: $F=4.56$, $p=0.012$), and non-parametric validation (Kruskal-Wallis: $H=9.87$, $p=0.007$). Post-hoc Tukey tests identified significant differences in fluconazole susceptibility between *C. albicans* and non-albicans species ($p < 0.01$).

4.3. Risk Factors

Significant risk factors included mouth sores (60%, oral, $X^2 = 18.5$, $p < 0.01$), white patches (45%, oral, $X^2 = 15.2$, $p < 0.01$), nausea (30%, GI, $X^2 = 12.3$, $p < 0.01$), constipation (25%, GI, $X^2 = 10.8$, $p < 0.01$), vaginal discharge (80%, VVC, $X^2 = 45.2$, $p < 0.001$), and pain during sex (65%, VVC, $X^2 = 38.7$, $p < 0.001$). These associations were consistent across infection sites (Table 3).

Discussion

This study confirms a high prevalence of vulvovaginal candidiasis (26.6% for *C. albicans*, 8.4% for non-albicans species) among immunocompromised patients in Cameroon, driven by HIV prevalence and female predominance (87.2%) (Mohamed et al., 2022). Clotrimazole (100% sensitivity for oral *C. albicans*) and flucytosine (98% for VVC) remain highly effective, but fluconazole resistance (20% for *C. albicans*, 40% for non-albicans) and complete griseofulvin resistance (0%) highlight significant antimicrobial resistance challenges (Berman and Krysan, 2020; World Health Organization, 2025b). Non-albicans species, particularly *C. glabrata* and *C. tropicalis*, exhibit lower susceptibility, consistent with regional trends in Egypt and Ghana (ElFeky et al., 2016; Feglo and Narkwa, 2015).

Table 1. Demographic Characteristics and Prevalence

Characteristic	Overall (n=500)	Oral (n=17)	GI (n=29)	VVC (n=133)	Non-albicans (n=58)
Sex, Female, n (%)	436 (87.2)	14 (82.4)	24 (82.8)	133 (100)	50 (86.2)
Age, Mean \pm SD	31.2 \pm 7.2	30.8 \pm 6.9	32.1 \pm 7.5	31.0 \pm 7.0	31.5 \pm 7.3
Age 28-37, n (%)	256 (51.2)	9 (52.9)	15 (51.7)	68 (51.1)	30 (51.7)
Married, n (%)	297 (59.4)	10 (58.8)	17 (58.6)	80 (60.2)	35 (60.3)
Income <50,000 XAF, n (%)	278 (55.6)	9 (52.9)	16 (55.2)	75 (56.4)	32 (55.2)
Prevalence, % (95% CI)	-	3.4 (1.8-5.0)	5.8 (3.8-7.8)	26.6 (22.7-30.5)	11.6 (8.8-14.4)

Table 2. Risk Factor Prevalence and Associations

Risk Factor	Prevalence (%)	Associated Site	X^2 (p-value)
Mouth Sores	60	Oral	18.5 (<0.01)
White Patches	45	Oral	15.2 (<0.01)
Nausea	30	GI	12.3 (<0.01)
Constipation	25	GI	10.8 (<0.01)
Vaginal Discharge	80	VVC	45.2 (<0.001)
Pain During Sex	65	VVC	38.7 (<0.001)

Table 3. Susceptibility Patterns and Statistical Analysis

Site	n (%), 95% CI	Clotrimazole	Itraconazole	Flucytosine	Fluconazole	Griseofulvin
Oral (<i>C. albicans</i>)	17 (3.4), 1.8-5.0	100%	80%	70%	85%	0%
GI (<i>C. albicans</i>)	29 (5.8), 3.8-7.8	80%	95%	85%	75%	0%
VVC (<i>C. albicans</i>)	133 (26.6), 22.7-30.5	70%	85%	98%	80%	0%
Non-albicans	58 (11.6), 8.8-14.4	65%	70%	60%	60%	0%

$X^2 = 32.4$ (0.001), $F=4.56$ (0.012), $H=9.87$ (0.007)

Molecularly, **ERG11 mutations** in *C. albicans* disrupt ergosterol biosynthesis, contributing to azole resistance rates exceeding 50% in Cameroon (Africa and Abrantes, 2016). **Efflux pumps** (CDR1/CDR2 in *C. albicans* and *C. glabrata*, MDR1 in *C. tropicalis*) reduce intracellular drug concentrations, particularly for fluconazole (Kwamin et al., 2013). **FKS mutations** in *C. glabrata* drive emerging echinocandin resistance, complicating treatment (Perlin, 2017). **Biofilms**, prevalent in VVC, create physical barriers to antifungals, enhancing resistance (Nett and Andes, 2010). Compared to South Africa (lower azole resistance) and Ghana (fluconazole resistance 4.5–22.2%), Cameroon's high resistance is linked to unregulated antifungal access (Abrantes et al., 2014; Feglo and Narkwa, 2015). Limited diagnostic tools, such as molecular sequencing, further exacerbate resistance risks (Nguouana et al., 2017).

Limitations include the single-center design and lack of molecular sequencing data to confirm resistance mechanisms. **Strengths** include robust statistical analyses (chi-square, ANOVA, Kruskal-Wallis) and alignment with WHO AMR priorities. **Recommendations** include: - **Surveillance**: Implement routine antifungal susceptibility testing in hospitals. - **Stewardship**: Prioritize clotrimazole and flucytosine based on high sensitivity. -

Education: Conduct hygiene and antifungal use workshops for people living with HIV/AIDS (Shinta et al., 2025). Future research should focus on multi-center studies, non-albicans species prevalence, and molecular characterization of resistance mechanisms like ERG11 and FKS mutations

5. CONCLUSION

Candidiasis still stands as one of the most prevalent opportunistic infection among immune compromised individuals especially HIV patients. Antifungal resistance is also one of the reasons why these group of individuals come down with this infection hence the need for this study. From this study, Clotrimazole, itraconazole and flucytosine were susceptible for the treatment of *C. albicans* with fluconazole and griseofulvin being resistant across all sites. For the non-candida species, Clotrimazole, itraconazole, flucytosine, fluconazole, and griseofulvin showed lower susceptibility pattern which is therefore imperative to educate the population on the use of antifungal drugs and the adverse effects that comes with it if misused and also monitoring antifungal resistance will go a long way to curb the challenges face with drug resistance

REFERENCES

- Abrantes, P. M., Figueiredo-Carvalho, M. H. G., Silva, R. L., & Santos, A. L. (2014). Species distribution and in vitro antifungal susceptibility of yeasts isolated from bloodstream infections in Rio de Janeiro, Brazil. *Brazilian Journal of Microbiology*, 45(4), 1455–1462. <https://doi.org/10.1590/S1517-83822014000400039>
- Abrantes, P. M. D. S., McArthur, C. P., & Africa, C. W. J. (2014). Multi-drug resistant oral Candida species isolated from HIV-positive patients in South Africa and Cameroon. *Diagnostic Microbiology and Infectious Disease*, 79(2), 222–227. <https://doi.org/10.1016/j.diagmicrobio.2013.09.016>
- Africa, C. W. J., & Abrantes, P. M. (2016). Candida in African settings: Epidemiology and resistance. *Current Fungal Infection Reports*, 10(2), 64–71. <https://doi.org/10.1007/s12281-016-0256-8>
- Ambe, N. F., Nji, E., Nsagha, D. S., & Kamga, H. L. (2020). Antifungal susceptibility patterns of Candida species isolated from HIV-infected patients in Cameroon. *BMC Infectious Diseases*, 20, 450. <https://doi.org/10.1186/s12879-020-05187-3>
- Badiee, P., Alborzi, A., Shakiba, E., Zarei Mahmoudabadi, A., & Katiraei, F. (2017). Antifungal susceptibility of Candida species isolated from immunocompromised patients. *Iranian Journal of Microbiology*, 9(1), 26–32. <https://pubmed.ncbi.nlm.nih.gov/28491221/>

Berman, J., & Krysan, D. J. (2020). Drug resistance and tolerance in fungi. *Nature Reviews Microbiology*, 18(6), 319–331. <https://doi.org/10.1038/s41579-019-0323-2>

Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020). Candidiasis and mechanisms of antifungal resistance. *Antibiotics*, 9(6), 312. <https://doi.org/10.3390/antibiotics9060312>

ElFeky, D. S., Ghannam, R. A., & Abo-Shadi, M. A. (2016). Species identification and antifungal susceptibility pattern of *Candida* isolates from various clinical specimens. *Egyptian Journal of Medical Microbiology*, 25(2), 47–55.

Feglo, P., & Narkwa, P. (2015). Prevalence and antifungal susceptibility patterns of yeast isolates at a Ghanaian teaching hospital. *Annals of Clinical Microbiology and Antimicrobials*, 14, 32. <https://doi.org/10.1186/s12941-015-0089-3>

Freitas, A. L., et al. (2023). Trends in antifungal resistance among *Candida* species: A systematic global review. *Journal of Fungi*, 9(2), 112. <https://doi.org/10.3390/jof9020112>

Kasper, D. L., Fauci, A. S., Hauser, S. L., Longo, D. L., Jameson, J. L., & Loscalzo, J. (2005). *Harrison's principles of internal medicine* (16th ed.). McGraw-Hill.

Kwamin, F., Nartey, N. O., Codjoe, F. S., & Newman, M. J. (2013). Distribution of *Candida* species among HIV-positive patients with oropharyngeal candidiasis in Ghana. *Journal of Infection in Developing Countries*, 7(1), 41–45. <https://doi.org/10.3855/jidc.2441>

Lamont, R. J., & Jenkinson, H. F. (2006). *Oral microbiology at a glance*. Wiley-Blackwell.

Ngouana, T. K., Dzoyem, J. P., & Kouanfack, C. (2017). Distribution and antifungal susceptibility of *Candida* species from clinical isolates in Yaoundé, Cameroon. *Journal of Medical Mycology*, 27(4), 531–536. <https://doi.org/10.1016/j.mycmed.2017.05.001>

Nett, J. E., & Andes, D. R. (2010). Contributions of the biofilm matrix to *Candida* pathogenesis. *Journal of Fungi*, 4(1), 6. <https://doi.org/10.3390/jof4010006>

Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., ... & Sobel, J. D. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*, 62(4), e1–e50. <https://doi.org/10.1093/cid/civ933>

Perlin, D. S. (2017). Mechanisms of echinocandin antifungal drug resistance. *Annals of the New York Academy of Sciences*, 1354(1), 1–11. <https://doi.org/10.1111/nyas.12831>

Selmecki, A., Forche, A., & Berman, J. (2006). Aneuploidy and isochromosome formation in drug-resistant *Candida albicans*. *Science*, 313(5785), 367–370. <https://doi.org/10.1126/science.1128242>

Shinta, R., Sari, D. P., & Wahyuni, N. (2025). Emerging antifungal resistance patterns in *Candida* species: Clinical implications in Southeast Asia. *International Journal of Medical Mycology*, 14(2), 78–89. <https://doi.org/10.1016/j.ijmm.2025.02.005>

UNAIDS. (2019). *Global HIV & AIDS statistics — 2019 fact sheet*. UNAIDS. <https://www.unaids.org/en/resources/fact-sheet>

Vanden Bossche, H., Dromer, F., Improvisi, I., Lozano-Chiu, M., Rex, J. H., & Sanglard, D. (1998). Antifungal drug resistance in pathogenic fungi. *Medical Mycology*, 36(1), 119–128. <https://doi.org/10.1080/02681219880000061>

World Health Organization. (2025a). *WHO fungal priority pathogens list to guide research, development and public health action* (2nd ed.). WHO Press.

World Health Organization. (2025b). *Antifungal resistance surveillance report — Global trends 2025*. WHO Press.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

HOW TO CITE

Lem C.A., Asakizi A.N., & Duna F.E. (2026). *Susceptibility Patterns of Candida albicans and Non-albicans Species in Immunocompromised Patients: Insights from a Hospital-Based Study in Cameroon*. *IQ Research Journal*, 5(2), IQRJ-V05102-26005006. www.iqresearchjournal.com

